Pfizer Outlines Its Supply Strategy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Outlines Its Supply Strategy
John Kelly, vice-president of strategy and transitioning sites for Pfizer Global Supply, discusses the company's manufacturing and supply strategy and network.


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 7, Issue 11

As part of its strategy to increase commercial value, the company focuses on developing and maintaining partnerships with the company’s business units to support innovation across the product life cycle, drive revenue creation and enhancement, and optimize supply-chain security. From an organizational perspective, PGS operates nine operating units, seven that support Pfizer business units and two that are responsible for managing external supply and transitioning sites. The PGS operating units support business units in specialty care, primary care, oncology, emerging markets, established products, animal health, consumer healthcare, and nutrition. The functions of these units and PGS operating units that focus on external supply and transitioning sites are supported by global logistics and supply activities, quality operations, global manufacturing services, and network-enabling functions, such as finance, human resources, legal, and procurement.

Kelly emphasizes that the company’s supply strategy is shaped by various factors affecting the industry. “The product mix is changing,” says Kelly. “We see shifts not only in small molecules versus large molecules, but see the need to address supply challenges caused by the changing blockbuster model and a move to smaller-volume products.”

As part of those changes in product demand, as well as part of it integration with Wyeth, Pfizer announced plans to exit 13 sites during the next several years. The timing of specific exits will depend upon the complexity of operations, the amount of time needed for product transfers, and other business requirements. Earlier this year, Pfizer sold its manufacturing plant at Dun Laoghaire, Ireland to Amgen. The 37,000-m2 aseptic operations facility has freeze-dried product and liquid vial-filling operations. Pfizer sold its bulk biologics facility in Shanbally, Ireland, to the biopharmaceutical company BioMarin. Pfizer also recently sold its consumer healthcare manufacturing facility in Richmond, Virginia, to Fareva, a pharmaceutical and consumer-products company, which will continue to supply Pfizer with product from the facility.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here